Drug Profile
Human papillomavirus 16/18 vaccine recombinant bivalent - Xiamen Innovax
Alternative Names: Cecolin; Human papillomavirus (types 16 and 18) L1 virus-like particle vaccine - Xiamen Innovax; Human papillomavirus 16/18 bivalent vaccine recombinant - Xiamen; Human papillomavirus 16/18 vaccine - Xiamen; Recombinant human papillomavirus bivalent (type 16/18) vaccine - Xiamen InnovaxLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Xiamen Innovax Biotech
- Developer Beijing Wantai Bio-pharm; Xiamen Innovax Biotech; Xiamen University
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Human papillomavirus infections
Highest Development Phases
- Marketed Cervical cancer; Human papillomavirus infections
Most Recent Events
- 14 Dec 2023 Xiamen Innovax Biotech completes a phase-III clinical trial in Cervical cancer (Prevention, In adolescents, In children) in Ghana and Bangladesh (IM) (NCT04508309)
- 10 Jan 2023 Preregistration for Cervical cancer (Prevention, In adolescents, In adults, In children) in Kenya, Cambodia, Malaysia, Indonesia, Kazakhstan, Thailand (IM) before January 2023
- 10 Jan 2023 Registered for Cervical cancer (Prevention, In adults, In children, In adolescents) in Nepal (IM)